Peptides have long attracted attention in the scientific community due to their structural simplicity yet vast range of ...

Vasoactive Intestinal Peptide (VIP) has remained a molecule of considerable scientific interest since its initial characterization as a 28–amino acid neuropeptide with widespread distribution ...

Structure Therapeutics (GPCR) is stepping into the spotlight as it prepares to release topline data from its ACCESS trial of aleniglipron, an oral GLP 1 candidate for obesity, along with a same day ...

Pathway’s post-transformer architecture BDH integrated with NVIDIA AI and AWS cloud infrastructure Pathway model’s continuous learning, efficiency, and live observability is powered by NVIDIA AI ...

In 2018, the California state legislature set the goal of reaching net-zero carbon emissions by 2045 in the California Climate Crisis Act. In September of 2025, a team of Stanford researchers ...

Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

Regeneration is a fundamental biological process that restores damaged tissues and organs, and understanding its underlying mechanisms is crucial for ...